-+ 0.00%
-+ 0.00%
-+ 0.00%

ALNYLAM PHARMACEUTICALS - CONTINUOUS VUTRISIRAN TREATMENT DECREASES RISK OF RECURRENT CV EVENTS BY 50%

Reuters·11/09/2026 15:50:15

Please log in to view news